Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) sees FY15 KALYDECO net revenues $560M-$580M; Nanosphere, Inc. (Nasdaq:NSPH), Gevo, Inc. (Nasdaq:GEVO)

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) sees FY15 KALYDECO net revenues $560M-$580M. FY15 revenue consensus $1.19B. KALYDECO net revenues reflect use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; use of KALYDECO in some people in the United States with the R117H mutation following FDA approval in late 2014.VRTX traded in the red and closed at $121.26 for the day. The stock saw a change of $2.41(1.95%) with a volume of 1,830,552 shares. VRTX has a market cap of $29.17B.

 

Nanosphere, Inc. (Nasdaq:NSPH) announces receipt of FDA warning letter. Nanosphere announced that it has received a warning letter from the FDA resulting from inspections of the company's facility in Northbrook, Illinois by the FDA's Chicago District Office that occurred in March 2014. The warning letter relates to deficiencies in the company's quality system regulation. NSPH is part of the Healthcare sector in Medical Instruments & Supplies industry. The stock closed for the day at $0.31 with a change of $0.00 or 0.62%. NSPH traded in a range of $0.28 to $035 through the day. The stock’s 52 week range is $0.22 to $2.69.

 

Gevo, Inc. (Nasdaq:GEVO) files to sell common stock and warrants. Gevo announced that it intends to offer and sell, subject to market and other conditions, common stock units. Each common stock unit will consist of one share of common stock, Series A warrants to purchase a certain number of shares of common stock and Series B warrants to purchase a certain number of shares of common stock. The units are to be sold by Gevo subject to market and other conditions in an underwritten public offering. Cowen and Company, LLC is acting as sole manager. The closing for GEVO was $0.2560 at the day’s end. It was a change of $0.0210. GEVO saw a market cap of $25.24M.